Close Menu

NEW YORK – German rare disease company Centogene on Thursday reported a 13 percent year-over-year revenue decrease in Q3 caused mainly by non-recurring upfront payments by two pharmaceutical partners a year ago.

"We're driving solid performance that is much better than what it might appear on paper," said Centogene CEO Arndt Rolfs during a conference call to discuss the financial results.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
26

As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.